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Abstract
Background: Rizatriptan is an effective and fast acting drug for the acute treatment of migraine.
Some nonsteroidal anti-inflammatory drugs (NSAID) have also demonstrated efficacy in treating
migraine attacks. There is evidence that the combination of a triptan and a NSAID decreases
migraine recurrence in clinical practice. The primary aim of this randomized open label study was
to assess the recurrence rates in migraine sufferers acutely treated with rizatriptan (RI) alone vs.
rizatriptan plus a COX-2 enzyme inhibitor (rofecoxib, RO) vs. rizatriptan plus a traditional NSAID
(tolfenamic acid, TO). We were also interested in comparing the efficacy rates within these three
groups.
Methods: We assessed 45 patients from a headache clinic in Rio de Janeiro (35 women and 10
men, ages 18 to 65 years, mean 37 years). Patients with IHS migraine were randomized to one out
of 3 groups, where they had to treat 6 consecutive moderate or severe attacks in counterbalanced
order. In group 1, patients treated the first two attacks with 10 mg RI, the third and fourth attacks
with RI + 50 mg RO and the last attacks with RI + 200 mg of TA. In group 2, we began with RI +
TA, followed by RI, and RI + RO. Group 3 treated in the following order: RI + RO, RI + TA, RI
alone. The presence of headache, nausea and photophobia at 1, 2 and 4 hours, as well as recurrence
and side effects were compared.
Results: A total of 33 patients finished the study, treating 184 attacks. The pain-free rates at 1 hour
were: RI: 15.5%; RI + RO: 22.6%; RI + TA: 20.3%(NS). Pain-free rates at 2 h were: RI: 37.9%; RI +
RO: 62.9%, and RI + TA: 40.6% (p = 0.008 for RI vs. RI + RO; p = 0.007 for RI + RO vs. RI + TA,
NS for RI vs RI + TA). At 4 h, pain-free rates were: RI: 69%; RI + RO: 82.3%; RI + TA: 78.1% (NS
for all comparisons). The combination of RI + RO was superior to RI and to RI + TA in regard of
the absense of nausea and photophobia at 4 hours. Recurrence (after being pain-free at 2 h) was
observed in 50% of patients treated with RI, in 15,4% of those treated with RI + RO, and in 7,7%
of those treated with RI + TA.
Conclusions: Despite the methodological limitations of this study, the combination of RI and RO
revealed a higher response rate at 2 hours. Recurrence was also clearly decreased with both
combinations in relation to the use of RI alone. Controlled studies are necessary to provide
additional evidence.
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Background
Triptans are effective drugs for the acute treatment of
migraine, and the drugs of choice for disabling migraine
attacks [1-4]. Rizatriptan (RI) is a fast acting triptan with
good efficacy at 2 hours. Placebo-controlled studies for
the 10 mg RI tablet found a 2-hour therapeutic gain rang-
ing from 27% to 40%, with headache relief at 2 hours
ranging from 70 to 77% and a pain-free response at 2 h
ranging from 40% to 44% (Placebo response ranging
from 2 to 10%). The recurrence rate for the 10 mg tablet
ranges from 30% to 47% [5-7]. Although being a very
effective triptan, incomplete relief and recurrence may
cause frustration to an expressive number of patients
[8,9].
Some non-steroidal anti-inflammatory drugs (NSAIDs)
such as acetylsalicylic acid, ibuprofen, diclofenac,
naproxen sodium, mefenamic acid, tolfenamic acid and
lysine clonixinate have also demonstrated efficacy in the
acute treatment of migraine [10-12]. The combination of
a triptan and a NSAID seems to decrease headache recur-
rence and increase the efficacy, being an interesting alter-
native in clinical practice to selected patients [13-15].
Rofecoxib (RO) is a long-acting (half-life of 17 hours)
member of a new class of NSAIDs, which selectively
inhibits the COX-2 enzyme, being therefore better toler-
ated with regard to gastrointestinal side effects [16,17]. Its
combination with RI seems to decrease the headache
recurrence and to increase the therapeutic gain at 2 hours
[15]. Tolfenamic acid (TA) is a traditional NSAID with
proven efficacy in the acute treatment of migraine. Its
combination with sumatriptan also decreases headache
recurrence in clinical practice [12,13].
Accordingly, in this randomized open label study we com-
pared RI alone vs. RI plus RO vs. RI plus TA in the acute
treatment of moderate or severe migraine attacks.
Methods
Forty-five patients from a private headache clinic in Rio de
Janeiro, Brazil, (35 women and 10 men, ages from 18 to
65 years, with a mean of 37 years) were enrolled. All
patients received a diagnosis of migraine according to the
criteria proposed by the IHS (International Headache
Society) [18], and were randomized to one out of 3
groups, where they treated 6 consecutive attacks in coun-
terbalanced order. To be included, subjects had to present
2–8 migraine attacks in the previous three months, use
medications to treat their attacks and to be on stable dose
of preventive treatments other than NSAID for more than
one month. Patients with a history of active peptic disease
as those receiving treatment for any other major medical
or psychiatric conditions were excluded. The past history
of taking any of the 3 study medications was not consid-
ered for inclusion/exclusion.
Patients randomized to Group 1 treated their first two
consecutive moderate or severe attacks with 10 mg RI, the
third and fourth consecutive attacks with RI + 50 mg RO
and the last two consecutive attacks with RI + 200 mg of
TA. In group 2, we began with RI + TA, followed by RI, and
RI + RO. Patients in group 3 treated in the following order:
RI + RO, RI + TA, and RI alone. This method of randomi-
zation allowed each group to start and to finish with a dif-
ferent drug scheme. The Institutional Review Board of the
University Federal Fluminense at Rio de Janeiro approved
the study and all patients were informed that the purpose
of this study was to test potential differences in efficacy
and recurrence and gave informed consent.
We assessed the following endpoints: Pain-free rates at 1,
2 and 4 hours; recurrence at 24 hours (defined as the
recurrence of headache after being pain-free at 2 hours);
presence of nausea and photophobia at 1, 2, and 4 hours;
side effects at any time point after receiving the study drug.
Endpoints were assessed trough an objective written
report to be filled out by each patient during each of the
treated attacks, and were also derived from headache cal-
endars. Data assessing previous habits regarding the
patient's timing of acute treatment of migraine attacks
were not collected. All patients were informed that treat-
ing attacks at mild severity would be considered protocol
violations and would not be used to draw conclusions.
Data were analyzed separately for each time point (hour
1, 2, or 4). A logistic regression model was built to control
for efficacy of treatment, sequence of treatment and attack
number. The method of generalized estimating equations
was used to account for the correlation within subjects.
Nausea and photophobia were analyzed using just those
attacks where the symptom was present at baseline.
Results
Thirty-three patients completed the study and treated a
total of 184 moderate or severe migraine attacks. Fourteen
attacks (6 patients), treated when pain was mild, were not
included in the analysis. Four patients of each of the
groups did not fill out the reports adequately and/or did
not follow the correct order of taking study drugs. Baseline
intensity is summarized in Table 1. Group 1 treated 58
attacks (40 moderate, 18 severe), group 2 treated 62
attacks (44 moderate, 18 severe) and group 3 treated 64
attacks (41 moderate, 23 severe) (NS).
The pain-free rates at 1 hour were: RI: 15.5%; RI + RO:
22.6%; RI + TA: 20,3% (NS). Pain-free rates at 2 h were:
RI: 37.9%; RI + RO: 62.9%, and RI + TA: 40,6% (p = 0.008
for RI vs. RI + RO; p = 0.007 for RI + RO vs. RI + TA, NS
for RI vs RI + TA). At 4 h, pain-free rates were: RI: 69%; RI
+ RO: 82.3%; RI + TA: 78.1% (NS for all comparisons)
(Table 2).BMC Neurology 2004, 4 http://www.biomedcentral.com/1471-2377/4/10
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Nausea was present in 80 attacks (43.5%) at baseline (27
attacks of Group 1, in 28 attacks of Group 2 and in 25
attacks from Group 3). After 2 hours and 4 hours, less
patients treated with RI + RO had nausea than those
treated with the single use of RI (p = 0.017). At 4 hours,
less patients treated with RI + TA had nausea than those
treated with the single use of RI (p = 0.032). There were no
statistically significant differences between the attacks
treated with the combinations RI + RO and RI + TA in all
time points (Table 3).
Photophobia was present in 102 (55.4%) of the 184
treated attacks at baseline. After 2 hours and 4 hours less
patients treated with the RI + RO had photophobia than
those treated with the single use of RI (respectively p =
0.010 and p = 0.023) or with the RI + TA (p = 0.003 and
p = 0.015) (Table 4).
Recurrence was observed in 50% of the attacks treated
with RI alone compared to 15,4% of those attacks treated
with the combination of RI +RO, and 7.7% of those
attacks treated with the combination of RI + TA. (Table 5,
p < 0.01 for RI vs. RI + RO; p < 0.01 for RI vs. RI + TA;
p=NS for RI + RO vs. RI + TA).
Adverse events were observed in 15 (25.8%) attacks
treated with RI, 17 (27.4%) treated with RI + RO, and 21
(32.8%) attacks treated with RI + TA (NS for all compari-
sons). Adverse events were mild and transient. In the
group treated with RI alone, the most frequent adverse
events were somnolence (8.6% of the attacks) and dizzi-
Table 1: Number of attacks by treatment and baseline intensity
RI RI + RO RI + TA
n%n%n%
Moderate 40 69.0 44 71.0 41 64.1
Severe 18 31.0 18 29.0 23 35.9
Total 58 100.0 62 100.0 64 100.0
RI: rizatriptan; RO: rofecoxib; TA: tolfenamic acid
Table 2: Pain free rates at consecutive timepoints.
Treatment 1 hour n/N (%) 2 hours n/N (%) 4 hour n/N (%)
RI 9/58 (15.5%) 22/58 (37.9%) 40/58 (69%)
RI + RO 14/62 (22.6%) 39/62 (62.9%) 60/62 (82.3%)
RI + TA 13/64 (20.3%) 26/64 (40.6%) 50/64 (79.1%)
P value NS for all comparisons P = 0.008 for RI vs RI + RO
P = 0.009 for RI vs RI + TA
NS for RI + RO vs RI + TA
NS for all comparisons
RI: rizatriptan; RO: rofecoxib; TA: tolfenamic acid; n: number of attacks with nausea; N: number of treated attacks.
Table 3: Absence of nausea at consecutive timepoints.
Treatment 1 hour n/N (%) 2 hours n/N (%) 4 hour n/N (%)
RI 7/27 (25.9%) 12/27 (44.4%) 17/27 (63%)
RI + RO 18/28 (35.7%) 20/28 (71.4%) 24/28 (85.7%)
RI + TA 5/25 (20%) 17/25 (68%) 22/25 (88%)
P value NS for all comparisons P = 0.01 for RI vs RI + RO
P = 0.09 for RI vs RI + TA
NS for RI + RO vs RI + TA
P = 0.04 for RI vs RI + RO
P = 0.03 for RI vs RI + TA
NS for RI + RO vs RI + TA
RI: rizatriptan; RO: rofecoxib; TA: tolfenamic acid; n: number of attacks with nausea; N: number of treated attacks.BMC Neurology 2004, 4 http://www.biomedcentral.com/1471-2377/4/10
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ness (8.6%). In the group treated with RI + RO, dyspepsia
happened in 4.8% of the attacks. Chest pain and tachycar-
dia were observed in one attack each. In the group treated
with RI + TA, dyspepsia happened in 6.2% of the attacks.
Discussion
This prospective randomized study demonstrated that the
combination of RI and a NSAID is associated with better
efficacy, decrease of associated symptoms, and decrease
on recurrence rates, compared to RI alone. However, our
data must be analyzed with caution. First, this is an open
study with inherent methodological flaws. Second, our
sample size is small, which may explain recurrence rates
of RI higher than usually presented in controlled studies.
Third, we didn't assess patient's satisfaction with each of
the chosen drug regimens. We tried to reduce the limita-
tions by randomizing patients in counterbalanced order,
thus reducing bias and increasing statistical power.
The triptans are a class of compounds acting through an
agonistic action at 5-HT 1B/1D receptors. Incomplete relief
in some patients, as well as recurrence of pain after com-
plete relief, may counteract adherence by not addressing
patient's expectations toward the acute migraine treat-
ment [8,9,19]. In a previous study, we had already
suggested that the combination of a triptan plus a NSAID
improves efficacy in clinical practice not only due to the
decrease in the recurrence rates, but also due to better effi-
cacy [13-15].
This study aimed to further investigate this hypothesis, by
assessing the efficacy of a long-acting NSAID with proven
efficacy in the acute treatment of migraine [20] combined
with RI, as well as RI associated with a traditionally effec-
tive NSAID. TA was chosen due to its action in the leuko-
triene synthesis as well [21-23].
Our findings are supported by previous studies. A study
assessing the efficacy of sumatriptan plus TA showed a
reduction in the recurrence rate from 62,5% to 23,8%;
with the combination of naproxen sodium plus
sumatriptan, the recurrence rates were 59% and 25.5%. A
study assessing the efficacy of RI + RO showed recurrence
rates of 53% and 20% [13-15]. Interestingly, in our study
the combination of RI +RO was significantly better not
only compared to the use of RI alone but also compared
to RI + TA with regard to pain free measures at 2 hours and
photophobia at 1, 2 and 4 hours.
The figures obtained in the present study were different
than those we observed in a previous trial comparing 10
mg RI with 10 mg RI + 25 mg RO [15]. In that study,
respectively 42%, 76.5% and 87.6% of the attacks treated
with the combination of RI + RO were pain free at 1, 2 and
4 hours. With regard to nausea, 49.1%, 79.2% and 90.6%
of the attacks with nausea at baseline were nausea free at
the time points 1, 2 and 4 hours. Although not significant,
there was a trend for the superiority of the combination
group over those taking RI alone, which was confirmed in
the present trial.
Rofecoxib shows clinical efficacy in studies of patients
with osteoarthritis and rheumatoid arthritism, similar to
diclofenac, naproxen and ibuprofen, all proven effective
in the acute treatment of migraine [10,24,25]. A recent
controlled study demonstrated the superiority of RO 25
mg and RO 50 mg against placebo. Both doses were more
effective in providing headache relief, as well as improv-
ing nausea and photophobia [20]. Its use in the short-
Table 4: Absence of photophobia at consecutive timepoints.
Treatment 1 hour n/N (%) 2 hours n/N (%) 4 hour n/N (%)
RI 8/32 (25%) 15/32 (46.9%) 23/32 (71.9%)
RI + RO 15/34 (44.1%) 26/34 (76.5%) 32/34 (94.1%)
RI + TA 8/36 (22.2%) 17/36 (47.2%) 26/36 (72.2%)
P value P = NS for RI vs RI + RO
P = NS for RI vs RI + TA
P = 0.02 for RI + RO vs RI + TA
P = 0.01 for RI vs RI + RO
P = NS for RI vs RI + TA
P = 0.003 for RI + RO vs RI + TA
P = 0.01 for RI vs RI + RO
P = NS for RI vs RI + TA
P = 0.01 for RI + RO vs RI + TA
RI: rizatriptan; RO: rofecoxib; TA: tolfenamic acid; n: number of attacks with photophobia; N: number of treated attacks.
Table 5: Recurrence rates according treatment group.
Treatment Recurrence Rate n/N (%)
RI 11/22 (50%)
RI + RO 6/39 (15.4%)
RI + TA 2/26 (7.7%)
P value P < 0.01 for RI vs RI + RO
P < 0.01 for RI vs RI + TA
P = NS for RI + RO vs RI + TA
RI: rizatriptan; RO: rofecoxib; TA: tolfenamic acid; n: attacks where 
recurrence were observed; N: number of treated attacks.BMC Neurology 2004, 4 http://www.biomedcentral.com/1471-2377/4/10
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term prevention of peri-menstrual migraine has been also
suggested in an open study [26]. In addition to its proven
efficacy, RO is followed by a significant lower incidence of
upper-gastrointestinal adverse events, such as perfora-
tions, ulcers and bleeds [24,25].
Tolfenamic acid is not only effective in migraine attacks
but may have comparable efficacy, according to some
studies, with ergotamine and sumatriptan. Studies show
that TA may provide relief in up to 77% of the patients at
2 hours [21,27].
Conclusions
Drug combinations in migraine treatment are common
among specialists and have a long background of funda-
mentals. Different neurotransmitter systems may be
involved in migraine pathophysiology as well as different
mechanisms may be involved in a migraine attack. Target-
ing it, when treating the patient, does represent a potential
way of achieving better results. Attempts to increase effi-
cacy and achieve patient's expectations can also represent
the difference between being effective or keep the adher-
ence in a patient's treatment [28-30]. Further controlled
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